Wegovy 0.25 mg prefilled pen

Wegovy 0.25 mg Prefilled Pen

Wegovy 0.25 mg prefilled pen contains semaglutide, a GLP-1 receptor agonist used alongside a reduced-calorie diet and increased physical activity for weight management in eligible adults. The 0.25 mg strength is the recommended starting dose in the UK and is normally used during the first four weeks before gradual dose escalation under medical supervision.

Wegovy is a prescription-only medicine and should only be used following assessment and prescribing by an appropriately qualified healthcare professional.

What Is Wegovy 0.25 mg?

Wegovy 0.25 mg contains semaglutide, which mimics the action of the naturally occurring hormone GLP-1. GLP-1 receptor activation can influence appetite, food intake and blood glucose regulation.

The 0.25 mg strength is specifically designed as the starting dose. According to the current UK product information, treatment normally begins at 0.25 mg once weekly for weeks 1–4 before progressing to higher strengths as directed by a prescriber.

How Wegovy 0.25 mg Is Used

Wegovy is administered once a week as a subcutaneous injection. The injection should be used exactly as prescribed and patients should follow the instructions supplied with their pen.

The usual adult dose-escalation schedule is:

• Weeks 1–4: 0.25 mg once weekly
• Weeks 5–8: 0.5 mg once weekly
• Weeks 9–12: 1 mg once weekly
• Weeks 13–16: 1.7 mg once weekly
• From week 17: 2.4 mg once weekly maintenance dose

Dose escalation is intended to reduce the likelihood of gastrointestinal side effects. Your prescriber may delay escalation or adjust treatment if significant gastrointestinal symptoms occur.

Who May Be Prescribed Wegovy?

Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adults with obesity or overweight with at least one weight-related health condition, according to the current UK prescribing information.

Eligibility should be assessed by a qualified healthcare professional. Wegovy is not suitable for everyone.

Important Safety Information

Wegovy can cause side effects, particularly gastrointestinal symptoms such as nausea, vomiting, diarrhoea and constipation. Other important warnings and precautions apply, so patients should read the official patient information leaflet and discuss their medical history and current medicines with their healthcare professional.

Do not change your Wegovy dose without medical advice. If you experience severe or concerning symptoms while using semaglutide, seek appropriate medical attention.

Wegovy 0.25 mg Storage

Wegovy should be stored according to the manufacturer’s instructions. The medicine should not be used if it has been frozen or if the solution does not appear clear and almost colourless. Always check the current patient leaflet for detailed storage instructions.

Why Start With 0.25 mg?

The 0.25 mg strength is intended to introduce semaglutide gradually. Starting at a lower dose allows the body to adjust before the dose is increased. The UK prescribing information specifies gradual escalation over 16 weeks toward the standard 2.4 mg maintenance dose.

Related Weight Management Medicines

Learn more about other weight-management treatments available through our weight loss medicines category.

You can also read about Mounjaro (tirzepatide), Ozempic (semaglutide) and Rybelsus (semaglutide) to understand how different medicines compare.

Official Wegovy Information

For the most accurate and up-to-date prescribing information, consult the Wegovy information published on the electronic Medicines Compendium (emc).

Patients should also follow guidance from the UK Medicines and Healthcare products Regulatory Agency (MHRA).

Important Information

Wegovy 0.25 mg is a prescription-only medicine. This information is provided for educational purposes and does not replace advice from a doctor, pharmacist or other qualified healthcare professional. Always use Wegovy exactly as prescribed.